Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation ...

The assay is heat stable at ambient or elevated temperatures, bypassing the need for cold chain during transport and storage.

Your DNA is continually damaged by sources both inside and outside your body. One especially severe form of damage called a double-strand break involves the severing of both strands of the DNA double ...

Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth – STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc.

A new variation of the CRISPR-Cas9 gene editing system makes it easier to re-engineer massive quantities of cells for therapeutic applications. The approach, developed at Gladstone Institutes and UC ...

MSK researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in cancer.

The DNA was then treated with the enzyme methyltransferase, which recognizes the methylated cytosine and copies the methylation information to the DNA template.

Sequencing DNA by converting it into an accordion molecule Roche’s new sequencing-by-expansion instrument, due to launch in 2026, garners buzz at AGBT conference by Laurel Oldach ...

Nutcracker Therapeutics and Elegen see their mission as delivering scalable and low-cost RNA manufacturing for individualized therapies.

Elegen, Nutcracker Therapeutics to pilot cell-free manufacturing process for RNA-based personalized cancer therapeutics: San Francisco Tuesday, July 15, 2025, 11:00 Hrs [IST] Eleg ...